High Hematocrit on TRT: What Lowers It and When Phlebotomy Is Used

On testosterone therapy, a hematocrit of 54% or higher calls for a change to treatment, and the first step is usually a dose review. Drinking more water or trying diet tricks for a few months is not the plan. The American Urological Association (AUA) says an on-treatment hematocrit (the share of your blood made of red cells) of 54% or more "warrants intervention", with dose adjustment as first-line management in men whose testosterone levels are high (AUA 2018, Table 8). Sleep apnea, smoking, and dehydration at the time of the blood draw are worth checking alongside that, but none of them is a reason to stay above 54% while you wait.

Why does hematocrit rise on TRT?

Testosterone tells the body to make more red blood cells. In a randomized trial of older men with mobility limits, six months of testosterone gel raised hemoglobin by about 7% and hematocrit by about 10%. The rise came with higher erythropoietin (the kidney hormone that drives red cell production) and lower hepcidin and ferritin, which means the body was pulling more iron into new red cells (Bachman et al., J Gerontol 2014).

The effect depends on dose. In a 20-week trial, 121 young and older men received one of five weekly doses of testosterone enanthate, from 25 mg to 600 mg. Hemoglobin and hematocrit rose in a straight line with the dose, and the rise was larger in men aged 60 to 75 than in men aged 19 to 35 (Coviello et al., JCEM 2008). Those doses were set for research, not as treatment advice.

The form of testosterone matters too. The AUA reports abnormally high hemoglobin or hematocrit in 19% to 44% of men on short-acting injections, and higher rates of polycythemia with injections than with gels or other topical products (AUA 2018). A 2018 review reached the same conclusion: short-acting injectable testosterone carries a greater risk of erythrocytosis (too many red cells) than other formulations (Ohlander et al., Sex Med Rev 2018).

What number calls for action?

The AUA guideline gives three checkpoints:

• Before starting: measure hemoglobin and hematocrit and tell the patient about the higher risk of polycythemia (statement 11, Strong Recommendation, Grade A).
• Baseline above 50%: hold testosterone until the cause is explained. The guideline names polycythemia vera (a bone marrow disorder), living at altitude, obstructive sleep apnea, and tobacco use (Table 8).
• On treatment, 54% or higher: intervene (Table 8).

The Endocrine Society likewise recommends against starting testosterone in men with an elevated hematocrit or untreated severe obstructive sleep apnea (Endocrine Society 2018). Its guideline authors advise checking hematocrit at baseline, 3 to 6 months after starting, and then yearly (Endocrine Society plenary slides, 2018).

Why the threshold matters

The best data on harm are observational. A database study matched 5,842 men who developed a hematocrit of 52% or higher on testosterone with 5,842 men on testosterone whose hematocrit stayed normal. In the first year, major cardiac events or blood clots occurred in 5.15% of the high-hematocrit group and 3.87% of the normal group (odds ratio 1.35) (J Urol 2022). A study of this design shows an association and can't prove that the extra red cells caused the events. The 2018 review called the evidence linking testosterone to vascular complications limited (Ohlander et al., Sex Med Rev 2018). For more on the risks, see how dangerous high hematocrit is and what the risks are.

What actually lowers hematocrit on TRT?

A dose review comes first

AUA Table 8 sets out the order. If your on-treatment testosterone is high, the first step is a dose adjustment. If it is low-normal, the guideline suggests measuring SHBG (the protein that carries testosterone in the blood) and free testosterone. If SHBG is low or free testosterone is high, a dose adjustment should be considered. If total and free testosterone are both low or normal and hematocrit is still high, the guideline says to refer you to a hematologist (AUA 2018, Table 8).

The new dose is your prescriber's decision, based on your labs and symptoms. Don't change your dose on your own.

Formulation and injection schedule

Because injections raise hematocrit more than topical products, a prescriber may consider a change of formulation. Some prescribers also split a weekly injection into smaller, more frequent doses. A 2026 practical review describes more frequent, lower-dose injections as an optional tool when hematocrit trends suggest a smoother testosterone level would help, used together with a dose adjustment (Cureus 2026). That review is expert opinion, not a trial result.

Things that raise hematocrit on their own

Check these at the same time as the dose review.

• Sleep apnea. In 474 men on TRT, 13.1% developed a hematocrit of 52% or higher, and obstructive sleep apnea was linked to about twice the odds (odds ratio 2.09) after adjusting for age, BMI, and peak testosterone. It was a retrospective study from one clinic (Lundy et al., J Sex Med 2020). If you haven't been evaluated for sleep apnea, ask your prescriber whether you should be.
• Smoking. The AUA lists tobacco use as one of the causes to rule out when hematocrit is high (AUA 2018, Table 8).
• Dehydration at the draw. When plasma volume is low, hematocrit can read high without any extra red cells. Hematology reviews list this "relative polycythemia secondary to volume contraction" among the causes to consider before calling a result true erythrocytosis (Am J Hematol 2025). Being well hydrated for a draw can keep a reading honest. It does not lower a true high hematocrit caused by testosterone.

When is phlebotomy used?

Therapeutic phlebotomy means removing a unit of blood to bring hematocrit down. The evidence behind it is thin. A 2024 review found that guidelines mention phlebotomy alongside dose adjustment, yet evidence supporting its efficacy or safety for testosterone-induced erythrocytosis is lacking. It also noted that phlebotomy eventually depletes iron stores and lowers tissue oxygen, and it recommended shared decision-making before starting it (Endocr Connect 2024).

Phlebotomy also costs iron. In a large study of blood donors, 18% of returning male frequent donors had absent iron stores (ferritin under 12 ng/mL) and 47% had iron-deficient red cell production (Cable et al., Transfusion 2012). Testosterone itself already lowers ferritin (Bachman et al., J Gerontol 2014).

In practice, clinics use both levers. In the sleep apnea study above, among 37 men with high hematocrit and sleep apnea, 59.5% were managed by lowering the testosterone dose and 37.8% by phlebotomy (Lundy et al., J Sex Med 2020).

If you go to a blood center, US donor rules have no TRT-specific provisions. Centers ask whether you are donating to help others or to reduce your red cell mass, then apply standard donor eligibility, their therapeutic phlebotomy policies, and medical director review. Testosterone is measurable in blood products collected from men on TRT; what that means for recipients is not known (Transfus Med Rev 2026). For a longer look at each option, see this guide to lowering hematocrit.

Who should not start or continue without a review?

• Men with a baseline hematocrit above 50% until the cause is found (AUA Table 8).
• Men with untreated severe obstructive sleep apnea (Endocrine Society).
• Men on treatment with a hematocrit of 54% or higher, until the prescriber has reviewed the dose and testosterone levels (AUA Table 8).

Common questions

Will drinking more water lower my hematocrit?

Only if the high reading came from low plasma volume (Am J Hematol 2025). Water doesn't remove red cells, so it won't fix a high hematocrit caused by testosterone. If you were dehydrated at the draw, your prescriber may repeat the test.

Is 52% a problem?

The AUA threshold for intervention on treatment is 54% (AUA 2018, Table 8). Some studies use 52% as their cutoff for polycythemia, including the database study that linked it to more cardiac events and clots in the first year (J Urol 2022). A rising trend toward 54% is worth raising with your prescriber before you cross it.

Can I keep donating blood instead of changing my dose?

When on-treatment testosterone is high, the AUA's first-line step is a dose adjustment (AUA 2018, Table 8). Phlebotomy eventually depletes iron stores, and evidence for its efficacy and safety in testosterone-induced erythrocytosis is lacking (Endocr Connect 2024). Talk through both options with the clinician managing your TRT.

What about grapefruit juice or cutting red meat?

AUA Table 8 lists dose adjustment, SHBG and free testosterone testing, and hematologist referral. It doesn't list diet changes (AUA 2018, Table 8). Neither grapefruit juice nor a diet change is part of the AUA's management steps, and neither should delay a dose review.

Bottom line

On TRT, a hematocrit of 54% or higher calls for action now, and the AUA's first step is a dose adjustment when testosterone levels are high. Injections raise hematocrit more than topical products, and sleep apnea and smoking push it up further, so those are worth checking at the same time. Phlebotomy is used too, but it depletes iron, and evidence for its efficacy and safety here is lacking. AlphaMD providers review follow-up labs, including hematocrit, for patients on testosterone replacement therapy.